Welcome, Guest. Please login or register.
May 28, 2022, 04:17:41 pm

Login with username, password and session length


  • Total Posts: 335
  • Total Topics: 191
  • Online Today: 19
  • Online Ever: 518
  • (January 21, 2020, 05:24:49 pm)
Users Online
Users: 0
Guests: 9
Total: 9


Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Precision Medicine Can Benefit Pancreatic Cancer Patients  (Read 2300 times)

Offline Cancer Health Editors

  • Jr. Member
  • **
  • Posts: 56
    • View Profile
Precision Medicine Can Benefit Pancreatic Cancer Patients
« on: July 02, 2018, 01:49:54 pm »
Molecular profiling can provide clinically meaningful information to help people with pancreatic cancer and their providers select effective treatments, the Pancreatic Cancer Action Network (PanCAN) announced last week.

Results from a study published in the American Association for Cancer Research journal, Clinical Cancer Research, showed that pancreatic cancer patients who had “actionable” mutations and received matched targeted therapy had better outcomes than those who did not.

“There has been a longstanding notion that precision medicine cannot benefit pancreatic cancer patients,” said study coauthor and PanCAN chief science officer Lynn Matrisian, PhD, MBA. “We now have to rethink that position as this research exemplifies a changing tide in the way we should treat pancreatic cancer patients, ensuring molecular profiling is an integral part of their treatment journey.”



© 2022 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.